A cell-permeable 2'-benzyloxy griseofulvin derivative that displays enhanced mammalian cancer-selective toxicity (IC50 ≤2, ≤4, ≤12, and ≥30uM against panels of leukemia, myeloma, solid tumors, and non-malignant cell lines, respectively), but little antifungal activity, by activating spindle-assembly-checkpoint without affecting microtubule kinetochore attachment. Cancer cells are reported to undergo multipolar (MP) mitosis with normal or supernumerary centrosomes in the presence of GF-15, resulting in subsequent apoptotic cell death. Shown to retard HT29 colon cancer & OPM2 myeloma tumor expansion in mice (20mg/kg/day i.p.) in vivo. GF-15 half-life is expected to be least 48h in cultures.
Storage and Stability:May be stored at 4°C. For long-term storage, aliquot and store at 4°C. Do not freeze. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
![RubR1 Activator, GF-15 (2'-Benzyloxy-2'-demethoxygriseofulvin, (2S,6'R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1'-(2'-benzyloxy-6'-methylcyclohex-2'-en-4'-one), (2S,5'R)-3'-benzyloxy-7-chloro-4,6-dimethoxy-5'-methyl-spiro(benzofuran-2,4'-cyclohex-2-ene)-1',3-dione, (1'S,6'R)-2'-(benzyloxy)-7-chloro-4,6-dimethoxy-6'-methyl-3H-spiro(benzofuran-2,1'-cyclohex[2]ene)-3,4'-dione, ...](https://aimg.as-1.co.jp/c/85/2076/50/85133520.jpg)